Cancer immunology
This article may be too technical for most readers to understand.(November 2012) |
Cancer immunology (immuno-oncology) is an interdisciplinary branch of
Definition
Cancer immunology is an interdisciplinary branch of biology concerned with the role of the
Tumor antigens
Tumors may express tumor antigens that are recognized by the immune system and may induce an immune response.[6] These tumor antigens are either TSA (Tumor-specific antigen) or TAA (Tumor-associated antigen).[7]
Tumor-specific
Tumor-specific antigens (TSA) are antigens that only occur in tumor cells.
Tumor-associated antigens
Tumor-associated antigens (TAA) are present in healthy cells, but for some reason they also occur in tumor cells.[7] However, they differ in quantity, place or time period of expression.[11] Oncofetal antigens are tumor-associated antigens expressed by embryonic cells and by tumors.[12] Examples of oncofetal antigens are AFP (α-fetoprotein), produced by hepatocellular carcinoma, or CEA (carcinoembryonic antigen), occurring in ovarian and colon cancer.[13][14] More tumor-associated antigens are HER2/neu, EGFR or MAGE-1.[15][16][17]
Immunoediting
Cancer immunoediting is a process in which immune system interacts with tumor cells. It consists of three phases: elimination, equilibrium and escape. These phases are often referred to as "the three Es" of cancer immunoediting. Both adaptive and innate immune system participate in immunoediting.[18]
In the elimination phase, the immune response leads to destruction of tumor cells and therefore to tumor suppression. However, some tumor cells may gain more mutations, change their characteristics and evade the immune system. These cells might enter the equilibrium phase, in which the immune system does not recognise all tumor cells, but at the same time the tumor does not grow. This condition may lead to the phase of escape, in which the tumor gains dominance over immune system, starts growing and establishes immunosuppressive environment.[19]
As a consequence of immunoediting, tumor cell clones less responsive to the immune system gain dominance in the tumor through time, as the recognized cells are eliminated. This process may be considered akin to Darwinian evolution, where cells containing pro-oncogenic or immunosuppressive mutations survive to pass on their mutations to daughter cells, which may themselves mutate and undergo further selective pressure. This results in the tumor consisting of cells with decreased immunogenicity and can hardly be eliminated.[19] This phenomenon was proven to happen as a result of immunotherapies of cancer patients.[20]
Tumor evasion mechanisms
- CD8+ cytotoxic T cells are a fundamental element of anti-tumor immunity. Their TCR receptors recognise antigens presented by MHC class I and when bound, the Tc cell triggers its cytotoxic activity. MHC I are present on the surface of all nucleated cells. However, some cancer cells lower their MHC I expression and avoid being detected by the cytotoxic T cells.[21][22] This can be done by mutation of MHC I gene or by lowering the sensitivity to IFN-γ (which influences the surface expression of MHC I).[21][23] Tumor cells also have defects in antigen presentation pathway, what leads into down-regulation of tumor antigen presentations. Defects are for example in transporter associated with antigen processing (TAP) or tapasin.[24] On the other hand, a complete loss of MHC I is a trigger for NK cells.[25] Tumor cells therefore maintain a low expression of MHC I.[21]
- Another way to escape cytotoxic T cells is to stop expressing molecules essential for co-stimulation of cytotoxic T cells, such as CD80 or CD86.[26][27]
- Tumor cells express molecules to induce apoptosis or to inhibit T lymphocytes:
- Tumor cells have gained resistance to effector mechanisms of NK and cytotoxic CD8+ T cell:
- by loss of gene expression or inhibition of apoptotic signal pathway molecules:
- by induction of expression or overexpression of antiapoptotic molecules:
Tumor microenvironment
- Production of CD4+ T cell into suppressive regulatory T cell (Treg)[34] by a contact dependent or independent stimulation. In a healthy tissue, functioning Tregs are essential to maintain self-tolerance. In a tumor, however, Tregs form an immunosuppressive microenvironment.[35]
- Tumor cells produce special cytokines (such as T-lymphocytes, dendritic cells and macrophages. They produce immunosuppressive TGF-β and IL-10.[36][25]
- Another producer of suppressive M2 macrophages. Their activation is promoted by TH type 2 cytokines (such as IL-4 and IL-13). Their main effects are immunosuppression, promotion of tumor growth and angiogenesis.[37]
- Tumor cells have non-classical MHC class I on their surface, for example HLA-G. HLA-G is inducer of Treg, MDSC, polarise macrophages into alternatively activated M2 and has other immunosuppressive effects on immune cells.[38]
Immunomodulation methods
Immune system is the key player in fighting cancer. As described above in mechanisms of tumor evasion, the tumor cells are modulating the immune response in their profit. It is possible to improve the immune response in order to boost the immunity against tumor cells.
- monoclonal anti-immune checkpoint inhibitors:
- CTLA-4 is a receptor upregulated on the membrane of activated T lymphocytes, CTLA-4 CD80/86 interaction leads to switch off of T lymphocytes. By blocking this interaction with monoclonal anti CTLA-4 antibody we can increase the immune response. An example of approved drug is ipilimumab.
- PD-1 is also an upregulated receptor on the surface of T lymphocytes after activation. Interaction PD-1 with PD-L1 leads to switching off or apoptosis. PD-L1 are molecules which can be produced by tumor cells. The monoclonal anti-PD-1 antibody is blocking this interaction thus leading to improvement of immune response in CD8+ T lymphocytes. An example of approved cancer drug is nivolumab.[39]
- Chimeric Antigen Receptor T cell
- This CAR receptors are genetically engineered receptors with extracellular tumor specific binding sites and intracellular signalling domain that enables the T lymphocyte activation.[40]
- Cancer vaccine
- Vaccine can be composed of killed tumor cells, recombinant tumor antigens, or dendritic cells incubated with tumor antigens (dendritic cell-based cancer vaccine) [41]
Relationship to chemotherapy
Obeid et al.[42] investigated how inducing immunogenic cancer cell death ought to become a priority of cancer chemotherapy. He reasoned, the immune system would be able to play a factor via a 'bystander effect' in eradicating chemotherapy-resistant cancer cells.[43][44][45][2] However, extensive research is still needed on how the immune response is triggered against dying tumour cells.[2][46]
Professionals in the field have hypothesized that 'apoptotic cell death is poorly immunogenic whereas necrotic cell death is truly immunogenic'.[47][48][49] This is perhaps because cancer cells being eradicated via a necrotic cell death pathway induce an immune response by triggering dendritic cells to mature, due to inflammatory response stimulation.[50][51] On the other hand, apoptosis is connected to slight alterations within the plasma membrane causing the dying cells to be attractive to phagocytic cells.[52] However, numerous animal studies have shown the superiority of vaccination with apoptotic cells, compared to necrotic cells, in eliciting anti-tumor immune responses.[53][54][55][56][57]
Thus Obeid et al.
However, advanced cancer patients with immunosuppression have left researchers in a dilemma as to how to activate their T-cells. The way the host dendritic cells react and uptake tumour antigens to present to CD4+ and CD8+ T-cells is the key to success of the treatment.[2][59]
See also
References
- PMID 25858803.
- ^ PMID 29208439.
- ^ S2CID 3355084.
- PMID 13404306.
- PMID 17386080.
- PMID 22190975.
- ^ a b c Storkus WJ, Finn OJ, DeLeo A, Zarour HM (2003). "Categories of Tumor Antigens". In Kufe DW, Pollock RE, Weichselbaum RR, Bast Jr RC, Gansler TS, Holland JF, Frei III E (eds.). Holland-Frei Cancer Medicine (6th ed.). BC Decker.
- PMID 23211628.
- PMID 23269792.
- PMID 8902388.
- PMID 28465452.
- PMID 6196931.
- S2CID 7112149.
- S2CID 6945964.
- PMID 22397502.
- S2CID 207196758.
- PMID 26342994.
- PMID 15032581.
- ^ PMID 24531241.
- PMID 23882157.
- ^ PMID 28397826.
- S2CID 3580894.
- PMID 29283429.
- PMID 25818339.
- ^ S2CID 119093972.
- PMID 16489051.
- PMID 10209504.
- PMID 25656654.
- PMID 26558876.
- PMID 38473345.
- PMID 32466293.
- PMID 19156528.
- PMID 25120954.
- PMID 31288845.
- PMID 20157609.
- PMID 21110315.
- PMID 31331034.
- PMID 30319626.
- PMID 30542345.
- PMID 30680780.
- ISBN 978-0-323-47978-3.
- ^ S2CID 12641252.
- S2CID 5169245.
- PMID 16760453.
- PMID 16977338.
- PMID 15246252.
- PMID 7548839.
- S2CID 12991980.
- S2CID 205470264.
- PMID 10662786.
- PMID 12391020.
- PMID 16247491.
- PMID 23390373.
- PMID 23170250.
- PMID 16782034.
- S2CID 27286647.
- PMID 12455034.
- S2CID 28596435.
- S2CID 223082.